Hims & Hers Health ( (HIMS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hims & Hers Health has experienced a downturn in its stock price following downgrades to a ‘Sell’ by both Bank of America Securities and Citi. The downgrades stem from concerns over potential shortfalls in the company’s fourth-quarter online revenue, signaling a possible slowdown in core growth. Additionally, there are regulatory risks tied to the company’s expansion into compounded semaglutide, which could face challenges from pharmaceutical companies lobbying the FDA. Citi’s downgrade also highlighted valuation concerns and negative corporate insider activity, including increased insider selling. These factors, along with competitive pressures and market uncertainties, have led to a cautious outlook for the stock.
More about Hims & Hers Health
YTD Price Performance: 10.87%
Average Trading Volume: 16,018,440
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.1B
For further insights into HIMS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.